Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.75 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.62 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17280045 | 0.96 | NR1H2 (0.75) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17117704 | 0.96 | NR1H2 (0.69) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17280046 | 0.96 | NR1H2 (0.69) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17570207 | 0.96 | NR1H2 (0.81) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17516081 | 0.93 | NR1H2 (0.75) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17279760 | 0.91 | NR1H2 (0.78) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17279769 | 0.89 | NR1H2 (0.75) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17279682 | 0.89 | NR1H2 (0.81) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23627138 | 0.87 | NR1H2 (0.78) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17570202 | 0.87 | NR1H2 (0.78) | NR1H2NR1H3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969726-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2017200210-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2017-11-23 | — | — | WO | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016072780-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.